Seroprevalence and immunological memory against SARS-CoV-2 in lung cancer patients: the SOLID study.

Autor:	Provencio M; Medical Oncology Department, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain., Rodríguez-Abreu D; Medical Oncology Department, Hospital Universitario Insular de Gran Canaria, Las Palmas, Spain., Ortega AL; Medical Oncology Department, Hospital Universitario de Jaén, Jaén, Spain., Serrano G; Medical Oncology Department, Hospital Universiario Infanta Leonor, Madrid, Spain., Aguado C; Medical Oncology Department, Hospital Clínico San Carlos, Madrid, Spain., Franco F; Medical Oncology Department, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain., Gutierrez V; Medical Oncology Department, Hospital Universitario Regional de Málaga, Málaga, Spain., López Vivanco G; Medical Oncology Department, Hospital Universitario Cruces, Barakaldo, Spain., Guirado M; Medical Oncology Department, Hospital General Universitario de Elche, Alicante, Spain., Benítez G; Medical Oncology Department, Hospital Universitario Insular de Gran Canaria, Las Palmas, Spain., Estival A; Catalan Institute of Oncology, Hospital Universitari Germans Trias i Pujol, B-ARGO, IGTP, Badalona, Spain., Calvo V; Medical Oncology Department, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain., Jiménez B; Medical Oncology Department, Hospital Universitario HM Sanchinarro, Madrid, Spain., Arasanz H; Medical Oncology Department, Complejo Hospitalario Navarra-Navarrabiomeed, Pamplona, Spain., Coves J; Medical Oncology Department, Hospital Universitari Son LLàtzer, Palma de Mallorca, Spain., Majem M; Medical Oncology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain., Massutí B; Medical Oncology Department, Hospital General Universitario de Alicante, Alicante, Spain., Vázquez S; Medical Oncology Department, Hospital Universitario Lucus Augusti, Lugo, Spain., Juan-Vidal O; Medical Oncology Department, Hospital Universitario y Politécnico La Fe, Valencia, Spain., Collazo-Lorduy A; Medical Oncology Department, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain., Gozálvez CL; Medical Oncology Department, Hospital Universitari Sant Joan de Reus, Reus, Spain., Del Barco E; Medical Oncology Department, Hospital Clínico Universitario de Salamanca, Salamanca, Spain., Rosero A; Medical Oncology Department, Hospital Universitario Infanta Cristina, Madrid, Spain., Bosch-Barrerra J; Medical Oncology Department, Institut Català d'Oncologia, Girona, Spain., Moreno MA; Medical Oncology Department, Hospital Universitario de Puerto Real, Cádiz, Spain., Mielgo-Rubio X; Medical Oncology Department, Hospital Universitario Fundación Alcorcón, Madrid, Spain., Villa JC; Medical Oncology Department, Hospital General Universitario Ciudad Real, Ciudad Real, Spain., López-Martin A; Medical Oncology Department, Hospital Universitario Severo Ochoa, Madrid, Spain., Córdoba JF; Medical Oncology Department, Hospital Universitario Arnau de Vilanova, Lleida, Spain., de Asís Aparisi F; Medical Oncology Department, Hospital General Universitario de Valencia, Valencia, Spain., Zafra M; Medical Oncology Department, Hospital General Universitario Morales Messeguer, Murcia, Spain., Mosquera J; Medical Oncology Department, Complejo Hospitalario Universitario A Coruña, A Coruña, Spain., Pérez Altozano J; Medical Oncology Department, Hospital Virgen de los Lirios, Alicante, Spain., Nadal E; Medical Oncology Department, Institut Català d'Oncologia, Hospitalet de Llobregat, Barcelona, Spain., Catot S; Medical Oncology Department, Altaia, Xarxa Assistencial Universitaria Manresa, Barcelona, Spain., Balsalobre J; Medical Oncology Department, Hospital General Universitario Santa Lucia, Cartagena, Murcia, Spain., de Portugal T; Medical Oncology Department, Complejo Hospitalario de Zamora, Zamora, Spain., Martín P; Medical Oncology Department, Hospital Clínico Universitario de Valencia, Valencia, Spain., Cuesta de Juan S; Laboratorio Central, Eurofins Megalab, Madrid, Spain., Cobo M; Medical Oncology Department, Hospital Universitario Regional de Málaga, Málaga, Spain.
Jazyk:	angličtina
Zdroj:	Translational lung cancer research [Transl Lung Cancer Res] 2022 Jan; Vol. 11 (1), pp. 53-63.
DOI:	10.21037/tlcr-21-504
Abstrakt:	Background: At present, we did not find any articles that studied seroprevalence and its persistence several months later in lung cancer patients in the setting of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Most patients with coronavirus disease 2019 (COVID-19) go on to develop antibodies (Abs) against viral proteins. However, it is not known how long these Abs last nor whether cancer treatments could affect the duration of immune response. Methods: This prospective, longitudinal, multicenter serological study in the setting of SARS-CoV-2 infection was carried out in 50 Spanish hospitals. Eligibility criterion was the diagnosis of any lung cancer. The determination of anti-SARS-CoV-2 IgG Abs was performed by qualitative immuno-enzymatic assay using enzyme-linked immunosorbent assay (ELISA) kit from NovaLisa whose Abs target the recombinant antigen N of the nucleocapsid of SARS-CoV-2. The first Ab determination was performed between April 21 and June 3, 2020. The second Ab determination was performed in all previously seropositive patients, between September 10 and November 20, 2020. Study objectives were to prospectively determine seroprevalence in unselected lung cancer patients during the first wave of the pandemic; the persistence of immunity; protection or lack thereof against reinfection; and the influence of treatments on maintenance or loss of immunity. Results: Of 1,500 patients, 128 were seropositive, overall prevalence of 8.5% seropositivity [95% confidence interval (CI): 7.2-10.1%]. Seventy-five percent were in active cancer treatment. Forty-seven point seven percent of IgG positive participants had experienced a symptomatic illness suspected of being infected with SARS-CoV-2 (95% CI: 38.8-56.6%). A second determination was performed on average 4.5 months later [interquartile range (IQR), 4.0-5.0 months] and obtained for 104 of the initially seropositive patients (81%), it could not be obtained in 24 patients, the majority due to death caused by disease progression (73%). In the second determination, IgG was not detected in 30.8% of patients. The severity of the infection, the need for hospitalization (P=0.032) and the presence of symptoms at diagnosis (P=0.02) were associated with persistence of immunity in the second determination. No variables or treatments received were associated with Abs loss. Conclusions: Immunity against SARS-CoV-2 does not appear to be compromised by treatment and persists beyond 4 months. Neither do mortality rates appear to be particularly high in this unselected population. Trial Registration: ClinicalTrials.gov identifier: NCT04407143. Competing Interests: Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://tlcr.amegroups.com/article/view/10.21037/tlcr-21-504/coif). MP reports grants, personal fees and non-financial support from BMS, Roche and Astrazeneca and personal fees from MSD and TAKEDA and unrelated to the present study. CA reports grants, personal fees and non-financial support from Roche, personal fees and non-financial support from Pierre Fabre and personal fees from Astrazeneca, BMS, MSD and Novartis and unrelated to the present study. MG reports personal fees from Roche, MSD and BMS and unrelated to the present study. GB reports personal fees and non-financial support from Roche and AstraZeneca, personal fees from Sanofi and non-financial support from MSD, Novartis, BMS, MERCK and unrelated to the present study. AE reports personal fees from Roche and MSD and non-financial support from BMS, Lilly, Pharmamar and unrelated to the present study. VC reports personal fees from Roche, BMS, MSD, AstraZeneca and unrelated to the present study. HA reports personal fees from AstraZeneca and unrelated to the present study. JC reports personal fees from Roche, AstraZeneca, Boehringer, BMS, Novartis and Pfizer and unrelated to the present study. MM reports personal fees an non-financial supports from BMS, AstraZeneca, Boehringer and Roche, personal fees from Kyowa Kyrin, Pierre Fabre, Novartis and Sanofi and non-financial support from MSD and Lilly and unrelated to the present study. OJV reports personal fees from: Boehringer, BMS, MSD, Roche, AstraZeneca, Lilly and Takeda and unrelated to the present study. CLG reports personal fees from MSD; Novartis, Kyowa Karin and unrelated to the present study. JBB reports grant and personal fees from Pfizer, grant from Pierre Fabre, personal fees from Roche, MSD, BMS, AstraZeneca, Novartis and Boehringer and unrelated to the present study. XM reports grant and personal fees from BMS, personal fees and non-financial support from Roche, personal fees from AstraZeneca and unrelated to the present study. FdAA reports personal fees from Takeda, Mylan, Archimedes, Boehringer and unrelated to the present study. EN reports grant and personal fees from BMS and MERCK, personal fees from Roche, Pfizer, MSD, AstraZeneca, Lilly and Amgen and unrelated to the present study. SC reports personal fees and non-finacial support from Roche and personal fees from Boehringer and unrelated to the present study. The other authors have no conflicts of interest to declare. (2022 Translational Lung Cancer Research. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu